Researcher Profile

Researcher Profile

David Waning, PhD

David Waning, PhD

Associate Professor, Department of Cellular and Molecular Physiology
Scientific Program:Next-Generation Therapies
View Website

Research Interests

Dr. David Waning's research focuses on the emerging importance of bone-muscle crosstalk in aging and disease.

The overarching goal of his research program is to discover and characterize molecular mechanisms that impair musculoskeletal health in disease and aging. Bone and muscle are tightly coupled during growth and development, and also during aging and disease yet the cellular and molecular mechanisms linking these two tissues are not well understood. The Waning lab is developing novel therapeutic approaches that improve musculoskeletal health in pre-clinical models of cancer and chemotherapy-induced sequelae, osteoporosis and aging.

The major aims of Dr. Waning's research are to identify and characterize signal mediators of bone-muscle crosstalk that affect musculoskeletal health. He is especially interested in identifying targets of oxidative stress that affect bone and muscle function; understanding muscle weakness in cachexia; cachexia and the relative contribution of muscle wasting and contractile dysfunction; and bone-muscle crosstalk in rare bone diseases.

  • Bone and Bones
  • Neoplasms
  • Muscles
  • Neoplasm Metastasis
  • Muscle Weakness
  • Proteins
  • Skeletal Muscle
  • Bone Neoplasms
  • Breast Neoplasms
  • Drug Therapy
  • Cachexia
  • DNA Damage

Recent Publications


Wilcox-Hagerty, J, Xu, H, Hain, BA, Arnold, AC & Waning, DL 2021, 'Bone metastases induce metabolic changes and mitophagy in mice', Experimental Physiology, vol. 106, no. 2, pp. 506-518.


Chakraborty, N, Waning, DL, Gautam, A, Hoke, A, Sowe, B, Youssef, D, Butler, S, Savaglio, M, Childress, PJ, Kumar, R, Moyler, C, Dimitrov, G, Kacena, MA & Hammamieh, R 2020, 'Gene-Metabolite Network Linked to Inhibited Bioenergetics in Association With Spaceflight-Induced Loss of Male Mouse Quadriceps Muscle', Journal of Bone and Mineral Research, vol. 35, no. 10, pp. 2049-2057.


Waning, DL, Guise, TA & Mohammad, KS 2019, 'A “Connexin” Responsible for the Fatal Attraction of Cancer to Bone', Cell Metabolism, vol. 29, no. 1, pp. 6-8.
Sturgeon, KM, Mathis, KM, Rogers, CJ, Schmitz, KH & Waning, DL 2019, 'Cancer- and Chemotherapy-Induced Musculoskeletal Degradation', JBMR Plus, vol. 3, no. 3, e10187.
Huot, JR, Essex, AL, Gutierrez, M, Barreto, R, Wang, M, Waning, DL, Plotkin, LI & Bonetto, A 2019, 'Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles', Cancers, vol. 11, no. 4, 571.
Hain, BA, Jude, B, Xu, H, Smuin, DM, Fox, EJ, Elfar, JC & Waning, DL 2020, 'Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy', Journal of Bone and Mineral Research, vol. 35, no. 2, pp. 368-381.


Wright, LE, Harhash, AA, Kozlow, WM, Waning, DL, Regan, JN, She, Y, John, SK, Murthy, S, Niewolna, M, Marks, AR, Mohammad, KS & Guise, TA 2017, 'Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo', Oncotarget, vol. 8, no. 5, pp. 8406-8419.
Ross, MH, Esser, AK, Fox, GC, Schmieder, AH, Yang, X, Hu, G, Pan, D, Su, X, Xu, Y, Novack, DV, Walsh, T, Colditz, GA, Lukaszewicz, GH, Cordell, E, Novack, J, Fitzpatrick, JAJ, Waning, DL, Mohammad, KS, Guise, TA, Lanza, GM & Weilbaecher, KN 2017, 'Bone-induced expression of integrin b3 enables targeted nanotherapy of breast cancer metastases', Cancer Research, vol. 77, no. 22, pp. 6299-6312.
Wang, H, Cai, S, Bailey, BJ, Saadatzadeh, MR, Ding, J, Tonsing-Carter, E, Georgiadis, TM, Gunter, TZ, Long, EC, Minto, RE, Gordon, KR, Sen, SE, Cai, W, Eitel, JA, Waning, DL, Bringman, LR, Wells, CD, Murray, ME, Sarkaria, JN, Gelbert, LM, Jones, DR, Cohen-Gadol, AA, Mayo, LD, Shannon, HE & Pollok, KE 2017, 'Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist', Journal of neurosurgery, vol. 126, no. 2, pp. 446-459.
Regan, JN, Mikesell, C, Reiken, S, Xu, H, Marks, AR, Mohammad, KS, Guise, TA & Waning, DL 2017, 'Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model', Frontiers in Endocrinology, vol. 8, no. DEC, 358.
Regan, JN, Trivedi, T, Guise, TA & Waning, DL 2017, 'The Role of TGFβ in Bone-Muscle Crosstalk', Current Osteoporosis Reports, vol. 15, no. 1, pp. 18-23.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)